Patents Assigned to Merck
  • Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
    Patent number: 4692441
    Abstract: Choline esters are used as drug absorption enhancing agents for drugs which are poorly absorbed from the nasal, oral, and vaginal cavities.
    Type: Grant
    Filed: August 16, 1985
    Date of Patent: September 8, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Jose Alexander, A. J. Repta, Joseph A. Fix
  • Benzofused lactams useful as cholecystokinin antagonists
    Patent number: 4692522
    Abstract: Benzofused lactams and pharmaceutically-acceptable salts thereof which are useful as cholecystokinin antagonists.
    Type: Grant
    Filed: June 6, 1986
    Date of Patent: September 8, 1987
    Assignee: Merck & Co., Inc.
    Inventors: William H. Parsons, Arthur A. Patchett
  • Targets for cathode sputtering
    Patent number: 4690745
    Abstract: Oxide-ceramic targets which can be used in magnetically enhanced cathode sputtering and which are based on hot-pressed indium oxide/tin oxide mixtures, which have a density of at least 75% of the theoretical density and which have been diminished to such an extent in the oxygen content compared with the stoichiometric composition that they have an electrical conductivity which corresponds to a specific resistance of 0.6 to 0.1 .OMEGA.. cm can be prepared by compression-molding the metal oxide mixture in a reducing atmosphere under a pressure of 50 to 600 kg/cm.sup.2 and at a temperature of 850.degree. to 1,000.degree. C.The targets can be used in direct-voltage sputtering.
    Type: Grant
    Filed: November 25, 1986
    Date of Patent: September 1, 1987
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventor: Hans D. Klein
  • Method, reagent and kit for the determination of nitrate ions
    Patent number: 4690902
    Abstract: A method for the colorimetric determination of nitrate ions comprises mixing the sample which is to be investigated with concentrated sulfuric acid and a color-generating compound of the formula ##STR1## wherein R is H, one equivalent of a cation, or C.sub.1-6 alkyl. A reagent and kit for colorimetric nitrate determination are also described.
    Type: Grant
    Filed: February 15, 1985
    Date of Patent: September 1, 1987
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventor: Roland Bitsch
  • Substituted hexahydro arylquinolizines as .alpha..sub.2 blockers
    Patent number: 4690928
    Abstract: Substituted hexahydro arylquinolizines and pharmaceutically acceptable salts thereof are selective .alpha..sub.6 -adrenergic receptor antagonists and thereby useful as antidepressants, antihypertensives, antidiabetics, antiobesity and platelet aggregation inhibitors.
    Type: Grant
    Filed: July 14, 1986
    Date of Patent: September 1, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Joel R. Huff, Joseph P. Vacca, John J. Baldwin
  • Acid stable heteropolysaccharide s-421
    Patent number: 4689160
    Abstract: Heteropolysaccharide S-421, prepared by fermentation of an unidentified Agrobacterium species ATCC 53378, has valuable properties as an acid stable heteropolysaccharide and is especially valuable for use in acidizing fluids.
    Type: Grant
    Filed: January 16, 1986
    Date of Patent: August 25, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Suzanne M. Steenbergen, Glen H. Best
  • Stabilizer for biological staining solutions
    Patent number: 4687489
    Abstract: Stabilized staining solutions containing dyestuffs and stabilizers, which contain dimethylammonium sulfate as a stabilizer.
    Type: Grant
    Filed: September 22, 1986
    Date of Patent: August 18, 1987
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Erwin Rieke, Renate Kaschek
  • Aralkylaminoethanol heterocyclic compounds
    Patent number: 4686222
    Abstract: Heterocyclic aminoethanols of the formulaHet--CHOH--CH.sub.2 --NH--aralkylwhere het is a 6-10 membered N heterocycle are disclosed. The compounds are useful as pharmaceuticals.
    Type: Grant
    Filed: October 3, 1985
    Date of Patent: August 11, 1987
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme (I.A.) Corp.
    Inventors: Joseph G. Atkinson, John J. Baldwin, David E. McClure
  • Anisotropic compounds and liquid crystal mixtures
    Patent number: 4686289
    Abstract: New anisotropic compounds with a cross-polarizing substituent have the formula (1) ##STR1## The increase in .epsilon..perp. is achieved by the polarizing group X, preferably the cyano group or a halogen atom, which is not laterally on the ring, as with the known compounds, but is on the bridge, that is to say is part of the main bridge bonding rings A and B to one another. Ring A has the formula (1a) or (1b) given herein and is always cycloaliphatic, while ring B can be identical to ring A or is an aromatic ring of the formula (1c) or (1d) herein. R.sup.1 and R.sup.2 are identical or different end groups of the formula (1e) herein.The radical X on the bridge causes less widening of the molecule than a radical X on a ring, which provides comparatively higher clear points and moreover enables aromatic rings to be omitted from the anisotropic compounds.
    Type: Grant
    Filed: February 25, 1986
    Date of Patent: August 11, 1987
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Tuong Huynh-Ba, Maged A. Osman
  • Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
    Patent number: 4686098
    Abstract: Recombinant DNA constructs having an avian retroviral long terminal repeat (LTR) ligated to the bovine growth hormone gene, were co-transformed into a mammalian cell (mouse) culture in order to obtain a stable cell culture secreting large amounts of bovine growth hormone. The transformed mouse cells were encapsulated in hollow fibers and implanted into animals, thereby producing circulating bovine growth hormone.
    Type: Grant
    Filed: May 14, 1984
    Date of Patent: August 11, 1987
    Assignee: Merck & Co., Inc.
    Inventors: John J. Kopchick, Frederick C. Leung, Thomas J. Livelli, Richard H. Malavarca
  • Lipid osmotic pump
    Patent number: 4685918
    Abstract: The instant invention is directed to a lipid osmotic pump, comprising:(A) a core, comprising:(i) a beneficial amount of at least one substantially water insoluble active agent which is lipid soluble and/or lipid wettable;(ii) a sufficient amount of at least one water immiscible lipid carrier, which is liquid at the temperature of intended use, to dissolve and/or suspend said active agent; and(iii) a sufficient amount of at least one osmotic agent to ensure release of said lipid carrier from the pump; and(B) surrounded by a water insoluble wall:(i) having a thickness of about 1 to 1000 microns;(ii) which is preferentially wetted by said lipid carrier over an aqueous solution of said osmotic agent;(iii) having a water permeability of about 1.times.10.sup.-18 to 4.times.10.sup.-15 cm.sup.
    Type: Grant
    Filed: February 1, 1985
    Date of Patent: August 11, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Gordon L. Amidon, Takeru Higuchi, Jennifer B. Dressman
  • Substituted cinnamyl-2,3-dihydrobenzofuran and analogs useful as anti-inflammatory agents
    Patent number: 4686235
    Abstract: Substituted cinnamyl-2,3-dihydrobenzofurans and analogs were prepared from the nucleophlic substitution of a cinnamylhalide with a 2,3-dihydrobenzofuran anion or an analog thereof. These compounds were found to be potent topical anti-inflammatory agents.
    Type: Grant
    Filed: August 12, 1985
    Date of Patent: August 11, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Michael N. Chang, Norman P. Jensen, Milton L. Hammond, Robert A. Zambias, John McDonald, Kathleen M. Rupprecht
  • Vaccine against varicella-zoster virus
    Patent number: 4686101
    Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. This gene can hybrid select messenger RNA which encodes and expresses a protein which reacts with human canvalescent zoster sera and with polyclonal monospecific antisera which neutralize viral infectivity. These proteins are useful for the preparation of a vaccine for VZV.
    Type: Grant
    Filed: August 2, 1985
    Date of Patent: August 11, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Ronald W. Ellis, Robert S. Lowe, Paul M. Keller, Andrew J. Davison
  • Substituted benzo[b]furo- and benzo[b]thieno quinolizines
    Patent number: 4686226
    Abstract: Substituted hexahydro arylquinolizines and pharmaceutically acceptable salts thereof are selective .alpha..sub.2 -adrenergic receptor antagonists and thereby useful as antidepressants, antihypertensives, ocular antihypertensives, antidiabetics, antiobesity and platelet aggregation inhibitors and modifiers of gastrointestinal motility.
    Type: Grant
    Filed: September 3, 1985
    Date of Patent: August 11, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Joel R. Huff, John J. Baldwin, Yojiro Sakurai, Joseph P. Vacca, James P. Guare, Jr.
  • 2-acylaminomethyl-1,4-benzodiazepine derivatives as CCK-antagonists
    Patent number: 4684646
    Abstract: A method of antagonizing the function of cholecystokinins in a disease state in mammals, especially in humans, which comprises administering a pharmaceutically-effective amount of certain 2-acylaminomethyl-1,4-benzodiazepine derivatives or their salts, alone or with a pharmaceutical carrier, with or without an adjuvant.
    Type: Grant
    Filed: November 18, 1985
    Date of Patent: August 4, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Raymond S. L. Chang, Ben E. Evans
  • Benzofused lactams as cholecystokinin antagonists
    Patent number: 4684645
    Abstract: Benzofused lactams and their use as antagonists of cholecystokinin are disclosed.
    Type: Grant
    Filed: November 18, 1985
    Date of Patent: August 4, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Raymond S. L. Chang, William H. Parsons
  • Leukotriene antagonists
    Patent number: 4683325
    Abstract: Compounds having the formula: ##STR1## are antagonists of leukotrienes of C.sub.4, D.sub.4 and E.sub.4, the slow reacting substance of anaphylaxis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Grant
    Filed: October 17, 1984
    Date of Patent: July 28, 1987
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Richard Frenette, Joshua Rokach, Masatoshi Kakushima, Robert N. Young
  • 3-O-benzyl-2,4,6-tridooxy-6-iodo-alpha-D-erythro-hexopyranide useful for preparing inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase
    Patent number: 4683314
    Abstract: Totally synthetic analogs of the known inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, compactin and mevinolin, are prepared from a chiral synthon derived from D-glucose which has the same chirality as the natural products.
    Type: Grant
    Filed: April 28, 1986
    Date of Patent: July 28, 1987
    Assignee: Merck & Co., Inc.
    Inventor: John D. Prugh
  • Process for the preparation of difficidin and derivative antibacterials
    Patent number: 4681846
    Abstract: Process for the preparation of difficidin and derivative antibacterial compounds of the formula: ##STR1## where R.sub.a and R.sub.b are members independently selected from the group consisting of hydrogen; alkali metal and alkaline earth metal cations; ammonium; and substituted ammonium; and R.sup.1 is hydrogen or hydroxy.
    Type: Grant
    Filed: May 6, 1985
    Date of Patent: July 21, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth E. Wilson, Richard L. Monaghan, Cheryl DeRiso, Sheldon B. Zimmerman, Otto D. Hensens, James E. Flor, Sagrario M. Del Val, Maria I. M. Fernandez
  • Substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones
    Patent number: 4680414
    Abstract: The invention relates to novel substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones, their analogs and their salts. These compounds are synthesized by methods selected from a number of synthetic routes depending on the particular structure, choice of intermediate or preferred reaction sequence. The compounds are useful for the treatment and prevention of injury to the brain and of edema due to head trauma, stroke (particularly ischemic), arrested breathing, cardiac arrest, Reye's syndrome, cerebral thrombosis, cerebral embolism, cerebral hemorrhage, cerebral tumors, encephalomyelitis, spinal cord injury, hydrocephalus, post-operative brain injury trauma, edema due to cerebral infections and various brain concussions.
    Type: Grant
    Filed: February 20, 1986
    Date of Patent: July 14, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Edward J. Cragoe, Jr., Otto W. Woltersdorf, Jr.